Study of bimekizumab for palmoplantar pustulosis
Treatments studied
Part of Mouth & dental, Skin clinical trials.
This trial tests a drug called bimekizumab for people with palmoplantar pustulosis (PPP), a skin condition causing painful pustules on the palms and soles. The goal is to see if the drug can clear these pustules and improve symptoms.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 18 years old.
- You have had palmoplantar pustulosis (PPP) for at least 6 months.
- Your PPP is moderate to severe, with more than 5 active pustules on your palms or soles.
- You are a candidate for systemic therapy (medication by mouth or injection) or phototherapy (light treatment).
- You have not taken any IL-17 blockers, including bimekizumab, before.
- You do not have other skin conditions like eczema or plaque psoriasis on your palms or soles.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a cream called delgocitinib for people with mild to severe palmoplantar pustulosis (PPP), a skin condition with pustules on the palms and soles. The cream is applied daily for 16 weeks to see if it improves symptoms and is safe.
This trial tests a new medication called picankibart for palmoplantar pustulosis, a skin condition causing painful pustules (small fluid-filled bumps) on the palms and soles. It's designed for people whose condition hasn't improved with standard treatments.
This study tests a new drug (Xeligekimab) for people with moderate to severe palmoplantar pustulosis — a condition causing painful blisters on the hands and feet. It may be an option if other treatments haven't worked well.
This trial tests whether combining two medications, tofacitinib and imatinib, can help treat moderate-to-severe palmoplantar pustulosis (PPP). PPP causes painful pustules on the palms and soles. This study is for people whose PPP is active and has not improved significantly on its own.
This trial tests a new oral medication, ivarmacitinib, for adults with palmoplantar pustulosis (PPP) who haven't gotten better with standard treatments. It aims to see if the drug is safe and effective for reducing the painful pustules on the palms and soles.
This trial tests a new drug, bimekizumab, for people with PRP, a rare skin condition. It may help reduce skin redness, scaling, and itching.
Hear when a new Palmoplantar Pustulosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.